A preclinical evaluation of minnelide as a therapeutic agent against pancreatic cancer

Science Translational Medicine

Volumn 4, Issue 156, 2012, Pages

  Chugh, Rohit ^a   Sangwan, Veena ^a   Patil, Satish P ^b   Dudeja, Vikas ^a   Dawra, Rajinder K ^a   Banerjee, Sulagna ^a   Schumacher, Robert J ^c   Blazar, Bruce R ^c   Georg, Gunda I ^d   Vickers, Selwyn M ^a   Saluja, Ashok K ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b University of Minnesota   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARGININE; ASPARTIC ACID; GEMCITABINE; GLYCINE; HISTIDINE; K RAS PROTEIN; MINNELIDE; PROTEIN P53; TRANSCRIPTION FACTOR PDX 1; TRIPTOLIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG DEGRADATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; SCID MOUSE; STRUCTURE ANALYSIS; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; CELL SURVIVAL; DITERPENES; DRUG SCREENING ASSAYS, ANTITUMOR; EPOXY COMPOUNDS; FEMALE; HUMANS; MICE; MICE, NUDE; MICE, SCID; NEOPLASM TRANSPLANTATION; ORGANOPHOSPHATES; PANCREATIC NEOPLASMS; PHENANTHRENES; PHOSPHORIC MONOESTER HYDROLASES;

EID: 84867793735     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004334     Document Type: Article

References (37)

1. A. Jemal, R. Siegel, J. Xu, E. Ward, Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010).
2. A. L. Warshaw, Z. Y. Gu, J. Wittenberg, A. C. Waltman, Preoperative staging and assessment of resectability of pancreatic cancer. Arch. Surg. 125, 230-233 (1990).
3. H. Burris, A. M. Storniolo, Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracil. Eur. J. Cancer 33 (Suppl. 1), S18-S22 (1997).
4. M. J. Moore, D. Goldstein, J. Hamm, A. Figer, J. R. Hecht, S. Gallinger, H. J. Au, P. Murawa, D. Walde, R. A. Wolff, D. Campos, R. Lim, K. Ding, G. Clark, T. Voskoglou-Nomikos, M. Ptasynski, W. Parulekar; National Cancer Institute of Canada Clinical Trials Group, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960-1966 (2007).
5. P. A. Phillips, V. Dudeja, J. A. McCarroll, D. Borja-Cacho, R. K. Dawra, W. E. Grizzle, S. M. Vickers, A. K. Saluja, Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res. 67, 9407-9416 (2007).
6. M. B. Antonoff, R. Chugh, D. Borja-Cacho, V. Dudeja, K. A. Clawson, S. J. Skube, B. S. Sorenson, D. A. Saltzman, S. M. Vickers, A. K. Saluja, Triptolide therapy for neuroblastoma decreases cell viability in vitro and inhibits tumor growth in vivo. Surgery 146, 282-290 (2009).
7. K. A. Clawson, D. Borja-Cacho, M. B. Antonoff, A. K. Saluja, S. M. Vickers, Triptolide and TRAIL combination enhances apoptosis in cholangiocarcinoma. J. Surg. Res. 163, 244-249 (2010).
8. V. Stella, J. J. Zygmunt, G. I. Georg, M. S. Safadi, Water-soluble prodrugs of hindered alcohols. U.S. Patent 6,451,776 B2 (September 17, 2002).
9. H. A. Krebs, Chemical composition of blood plasma and serum. Annu. Rev. Biochem. 19, 409-430 (1950).
10. A. A. Yunis, G. K. Arimura, D. J. Russin, Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: Sensitivity to asparaginase. Int. J. Cancer 19, 128-135 (1977).
11. T. Iwamura, S. Taniguchi, N. Kitamura, H. Yamanari, A. Kojima, K. Hidaka, T. Setoguchi, T. Katsuki, Correlation between CA19-9 production in vitro and histological grades of differentiation in vivo in clones isolated from a human pancreatic cancer cell line (SUIT-2). J. Gastroenterol. Hepatol. 7, 512-519 (1992).
12. B. J. Drucker, F. M. Marincola, D. Y. Siao, T. A. Donlon, C. D. Bangs, W. D. Holder Jr., A new human pancreatic carcinoma cell line developed for adoptive immunotherapy studies with lymphokine-activated killer cells in nude mice. In Vitro Cell Dev. Biol. 24, 1179-1187 (1988).
13. W. H. Chen, J. S. Horoszewicz, S. S. Leong, T. Shimano, R. Penetrante, W. H. Sanders, R. Berjian, H. O. Douglass, E. W. Martin, T. M. Chu, Human pancreatic adenocarcinoma: In vitro and in vivo morphology of a new tumor line established from ascites. In Vitro 18, 24-34 (1982).
14. M. P. Kim, D. B. Evans, H. Wang, J. L. Abbruzzese, J. B. Fleming, G. E. Gallick, Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat. Protoc. 4, 1670-1680 (2009).
15. M. Erkan, C. Reiser-Erkan, C. W. Michalski, B. Kong, I. Esposito, H. Friess, J. Kleeff, The impact of the activated stroma on pancreatic ductal adenocarcinoma biology and therapy resistance. Curr. Mol. Med. 12, 288-303 (2012).
16. D. Mahadevan, D. D. Von Hoff, Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol. Cancer Ther. 6, 1186-1197 (2007).
17. G. C. Chu, A. C. Kimmelman, A. F. Hezel, R. A. DePinho, Stromal biology of pancreatic cancer. J. Cell. Biochem. 101, 887-907 (2007).
18. M. Erkan, C. Reiser-Erkan, C. W. Michalski, J. Kleeff, Tumor microenvironment and progression of pancreatic cancer. Exp. Oncol. 32, 128-131 (2010).
19. B. Farrow, D. Albo, D. H. Berger, The role of the tumor microenvironment in the progression of pancreatic cancer. J. Surg. Res. 149, 319-328 (2008).
20. J. Kleeff, P. Beckhove, I. Esposito, S. Herzig, P. E. Huber, J. M. Löhr, H. Friess, Pancreatic cancer microenvironment. Int. J. Cancer 121, 699-705 (2007).
21. G12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469-483 (2005).
22. M. Singh, A. Lima, R. Molina, P. Hamilton, A. C. Clermont, V. Devasthali, J. D. Thompson, J. H. Cheng, H. Bou Reslan, C. C. Ho, T. C. Cao, C. V. Lee, M. A. Nannini, G. Fuh, R. A. Carano, H. Koeppen, R. X. Yu, W. F. Forrest, G. D. Plowman, L. Johnson, Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat. Biotechnol. 28, 585-593 (2010).
23. S. Jones, X. Zhang, D. W. Parsons, J. C. Lin, R. J. Leary, P. Angenendt, P. Mankoo, H. Carter, H. Kamiyama, A. Jimeno, S. M. Hong, B. Fu, M. T. Lin, E. S. Calhoun, M. Kamiyama, K. Walter, T. Nikolskaya, Y. Nikolsky, J. Hartigan, D. R. Smith, M. Hidalgo, S. D. Leach, A. P. Klein, E. M. Jaffee, M. Goggins, A. Maitra, C. Iacobuzio-Donahue, J. R. Eshleman, S. E. Kern, R. H. Hruban, R. Karchin, N. Papadopoulos, G. Parmigiani, B. Vogelstein, V. E. Velculescu, K. W. Kinzler, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806 (2008).
24. S. P. Dineen, C. L. Roland, R. Greer, J. G. Carbon, J. E. Toombs, P. Gupta, N. Bardeesy, H. Sun, N. Williams, J. D. Minna, R. A. Brekken, Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res. 70, 2852-2861 (2010).
25. T. Fujisawa, H. Nakashima, A. Nakajima, B. H. Joshi, R. K. Puri, Targeting IL-13Rα2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine. Int. J. Cancer 128, 1221-1231 (2011).
26. L. C. DeRosier, Z. Q. Huang, J. C. Sellers, D. J. Buchsbaum, S. M. Vickers, Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo. J. Gastrointest. Surg. 10, 1291-1300 (2006).
27. O. J. Becher, E. C. Holland, Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res. 66, 3355-3358 (2006).
28. S. Bisht, M. Mizuma, G. Feldmann, N. A. Ottenhof, S. M. Hong, D. Pramanik, V. Chenna, C. Karikari, R. Sharma, M. G. Goggins, M. A. Rudek, R. Ravi, A. Maitra, A. Maitra, Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer. Mol. Cancer Ther. 9, 2255-2264 (2010).
29. M. Hidalgo, Pancreatic cancer. N. Engl. J. Med. 362, 1605-1617 (2010).
30. K. P. Olive, M. A. Jacobetz, C. J. Davidson, A. Gopinathan, D. McIntyre, D. Honess, B. Madhu, M. A. Goldgraben, M. E. Caldwell, D. Allard, K. K. Frese, G. Denicola, C. Feig, C. Combs, S. P. Winter, H. Ireland-Zecchini, S. Reichelt, W. J. Howat, A. Chang, M. Dhara, L. Wang, F. Rückert, R. Grützmann, C. Pilarsky, K. Izeradjene, S. R. Hingorani, P. Huang, S. E. Davies, W. Plunkett,M. Egorin, R. H. Hruban, N. Whitebread, K.McGovern, J. Adams, C. Iacobuzio-Donahue, J. Griffiths, D. A. Tuveson, Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461 (2009).
31. P. P. Provenzano, C. Cuevas, A. E. Chang, V. K. Goel, D. D. Von Hoff, S. R. Hingorani, Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21, 418-429 (2012).
32. F. X. Sun, A. Tohgo, M. Bouvet, S. Yagi, R. Nassirpour, A. R. Moossa, R. M. Hoffman, Efficacy of camptothecin analog DX-8951f (exatecan mesylate) on human pancreatic cancer in an orthotopic metastatic model. Cancer Res. 63, 80-85 (2003).
33. V. L. Damaraju, D. Y. Bouffard, C. K. Wong, M. L. Clarke, J. R. Mackey, L. Leblond, C. E. Cass, M. Grey, H. Gourdeau, Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer. BMC Cancer 7, 121 (2007).
34. Z. H. Wang, H. Chen, H. C. Guo, H. F. Tong, J. X. Liu, W. T. Wei, W. Tan, Z. L. Ni, H. B. Liu, S. Z. Lin, Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo. Int. J. Oncol. 39, 1123-1131 (2011).
35. M. Zhao, Y. Tominaga, K. Ohuchida, K. Mizumoto, L. Cui, S. Kozono, H. Fujita, R. Maeyama, H. Toma, M. Tanaka, Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer. Cancer Sci. 103, 58-66 (2012).
36. P. K. Mazur, J. T. Siveke, Genetically engineered mouse models of pancreatic cancer: Unravelling tumour biology and progressing translational oncology. Gut 61, 1488-1500 (2012).
37. A. Aghdassi, P. Phillips, V. Dudeja, D. Dhaulakhandi, R. Sharif, R. Dawra, M. M. Lerch, A. Saluja, Heat shock protein 70 increases tumorigenicity and inhibits apoptosis in pancreatic adenocarcinoma. Cancer Res. 67, 616-625 (2007).